Inconclusion, the data suggested that β-elemene+paclitaxel can inhibit ovariancancer growth via down-regulation of the STAT3-NF-κB signaling pathway, whichmay be a potential therapeutic strategy for ovarian cancer therapy. This evidence concerns the gene NFKB1 and ovarian cancer.